Loading...
•
Sep 30, 2024
Safety Shot Q1 2025 Earnings Report
Safety Shot reported a decrease in revenue and a significant net loss for Q1 2025, primarily due to a strategic shift towards acquiring Yerbae Brands Inc. and a one-time inventory write-off in the previous year.
Key Takeaways
Safety Shot, Inc. experienced a substantial net loss of $5,326,933 in the first quarter of 2025, a significant improvement from the $15,674,671 loss in the same period last year. Revenue decreased to $42,101 from $170,732, attributed to a strategic redirection towards the acquisition of Yerbae Brands Inc. and a new marketing strategy. The company continues to operate with a negative working capital and accumulated deficits, raising substantial doubt about its ability to continue as a going concern.
Net loss significantly improved to $5,326,933 in Q1 2025 from $15,674,671 in Q1 2024.
Revenue decreased to $42,101 in Q1 2025, down from $170,732 in Q1 2024, due to a strategic shift and new marketing strategy.
Total operating expenses decreased to $5,411,325 in Q1 2025 from $12,956,552 in Q1 2024.
The company continues to face going concern doubts due to accumulated deficits and negative working capital.
Safety Shot
Safety Shot
Safety Shot Revenue by Segment
Safety Shot Revenue by Geographic Location
Revenue by Segment
Dietary Drink Supplement Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
The company anticipates continued significant costs in pursuit of its expansion and development plans, with a focus on new product formats and flavors. It also expects to implement a new marketing strategy in Q2 2025.
Positive Outlook
- Focus on developing new product formats and flavors for the Sure Shot Dietary Supplement.
- Implementation of a new marketing strategy in Q2 2025 to drive sales.
- Commitment to innovation and adaptability to evolving consumer demands.
- Leveraging partnerships with industry leaders and organizations to expand reach.
- Products are manufactured in GMP-adhering facilities, ensuring quality and safety.
Challenges Ahead
- Continued incurrence of significant costs for expansion and development plans.
- Negative working capital and accumulated deficits raise substantial doubt about going concern.
- Uncertainty regarding the impact of ongoing and future regulatory actions on business and operations.
- Potential for increased costs and delays if new drug approval is required for the product.
- Reliance on third-party manufacturers and clinical trial organizations introduces risks of supply chain disruptions and delays.